Ohio is currently home to 3199 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow
NCT03363373
Recruiting
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Gender:
ALL
Ages:
1 year and above
Trial Updated:
02/18/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Neuroblastoma
Register for Updates
Transformative Research in Diabetic Nephropathy
NCT02986984
Recruiting
This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (\> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/18/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Diabetic Nephropathies, Diabetic Glomerulosclerosis
Register for Updates
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
NCT06533527
Recruiting
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV). Primary Outcomes: * Residual gastric volume that precludes adequate endoscopic examination * Residual gastric volume that necessitates premature termination of the endoscopy procedure * Need for endotracheal intubation due to stomach contents. * Occurrence of aspiration events requiring extended observation/monitoring, unplanned therapeutics, and/or hos... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/17/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis
Register for Updates
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
NCT06016946
Recruiting
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.
Gender:
ALL
Ages:
All
Trial Updated:
02/17/2025
Locations: Ohio State University - Neurology, Columbus, Ohio
Conditions: Friedreich Ataxia
Register for Updates
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379
Recruiting
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
02/17/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Register for Updates
Methimazole in Patients With Progressive Glioblastoma
NCT05607407
Recruiting
The purpose of this study is to test the effectiveness, safety, and tolerability of a drug called Methimazole. The investigational drug, Methimazole is not FDA approved for brain tumors, but it is used to treat thyroid illnesses. Different doses of Methimazole will be given to several study participants with glioblastoma. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Glioblastoma, Glioma
Register for Updates
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
NCT05471908
Recruiting
Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
02/17/2025
Locations: Cincinnati Children's Hospital Medical Center - Main Campus, Cincinnati, Ohio
Conditions: Pneumonia, Urinary Tract Infections, Soft Tissue Infections, Gastroenteritis
Register for Updates
The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH
NCT05113381
Recruiting
The primary goal of this study is to assess the occurrence of flushing interventions to address occlusions during the treatment of interventricular hemorrhage (spontaneous primary IVH or secondary IVH due to ruptured aneurysm).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Wright State University/Premier Health, Dayton, Ohio
Conditions: Intraventricular Hemorrhage, Subarachnoid Hemorrhage
Register for Updates
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
NCT05030441
Recruiting
This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities in these patients. The study will also be offered in a decentralized, remote structure to patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Cleveland Clinic - Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Clonal Cytopenia of Undetermined Significance
Register for Updates
The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation
NCT04494295
Recruiting
This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery from last known well time will be explored.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Supratentorial Hemorrhage
Register for Updates
Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain
NCT03625752
Recruiting
The purpose of this study is to assess the effects of Transcranial Direct Current Stimulation (tDCS) in combination with Transcranial ultrasound (TUS) for the treatment of pain and functional limitations in subjects with Diabetic Neuropathic Pain.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
02/16/2025
Locations: University Hospitals Cleveland Medical Center/ Dahms Clinical Research Unit, Cleveland, Ohio
Conditions: Diabetic Neuropathies, Chronic Pain
Register for Updates
A U.S. Double-blind, Placebo-controlled Phase 2 Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder
NCT06809179
Recruiting
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/14/2025
Locations: Vistagen Clinical Site, Cleveland, Ohio
Conditions: Social Anxiety Disorder
Register for Updates